A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1135
- Registration Number
- NCT05714202
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇧🇷Liga Paranaense de Combate ao Cancer, Curitiba, Brazil
🇧🇷Hospital Regional do Cancer - Hospital de Esperança, Presidente Prudente, Brazil
A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT05703841
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
- Conditions
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 15000
- Registration Number
- NCT05702034
- Locations
- 🇺🇸
Shady Grove Office, Rockville, Maryland, United States
🇦🇺Box Hill Hospital, Box Hill, Australia
🇨🇦Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
- Conditions
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 73
- Registration Number
- NCT05663866
- Locations
- 🇫🇷
Hopital Europeen Georges-Pompidou, Paris, France
🇫🇷CHU Rouen Hopital Charles Nicolle, Rouen, France
🇰🇷Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of
A Study to Investigate Acute Respiratory Virus Infections in Participants at High Risk for Severe Illness
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 140
- Registration Number
- NCT05661604
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇨🇦Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸Fred Hutchinson Research Center, Seattle, Washington, United States
A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT05653427
- Locations
- 🇨🇳
The First Hospital of Jilin University, Chang Chun Shi, China
🇨🇳Beijing Cancer Hospital, Beijing, China
🇨🇳Zhejiang University First Hospital, Hang Zhou Shi, China
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 195
- Registration Number
- NCT05652335
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇯🇵The Cancer Institute Hospital of JFCR, Tokyo, Japan
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 650
- Registration Number
- NCT05572515
- Locations
- 🇺🇸
Michael E DeBakey VA Medical Center, Houston, Texas, United States
🇨🇦Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇵🇹Uls Gaia Espinho, Vila Nova de Gaia, Portugal
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT05564052
- Locations
- 🇹🇷
Ondokuz Mayis University, Atakum, Turkey
🇧🇷Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Brazil
🇧🇷Sociedade Beneficente de Senhoras - Hospital Sirio Libanes HSL Unidade Brasilia, Brasilia, Brazil
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1590
- Registration Number
- NCT05552222
- Locations
- 🇨🇳
The Second Xiangya Hospital of Central South Hospital, Changsha, China
🇨🇳The First Affliated Hospital Of Nanchang University, Nanchang, China
🇦🇹SCRI CCCIT gem GmbH, Salzburg, Austria